Hormonal
Tirzepatide, a dual GLP-1/GIP receptor agonist administered once weekly (5-15 mg), significantly reduces body weight and improves glycemic control in patients with type 2 diabetes and obesity, outperforming placebo, GLP-1 receptor agonists (semaglutide, dulaglutide), and basal insulins.
Tirzepatide is a once-weekly injection approved for type 2 diabetes and obesity. It works by mimicking two gut hormones (GLP-1 and GIP) to lower blood sugar and reduce appetite. Clinical trials show it leads to significant weight loss (up to 22% in obesity) and better blood sugar control than many existing medications, including standard GLP-1 drugs and insulin. Treatment starts at a low dose to manage side effects like nausea, which usually decrease over time.
Tirzepatide provided better efficacy than placebo and other commonly used glucose-lowering medications such as semaglutide 1 mg, dulaglutide, insulin degludec, and glargine... In people without diabetes, tirzepatide 5 to 15 mg once weekly for the treatment for obesity (SURMOUNT-1) resulted in substantial reductions in body weight (16.5% to 22.4%) over 72 weeks.
Why this rating
Based on multiple phase 3 randomized controlled trials (SURPASS program) and a dedicated obesity trial (SURMOUNT-1).
Source
Efficacy and Safety of Tirzepatide in Type 2 Diabetes and Obesity Management
Rachel Sinha et al. · Journal of Obesity & Metabolic Syndrome · 2023
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →